- Home
- ACRS vs GALT Comparison
ACRS vs GALT Comparison
Compare ACRS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- GALT
- Stock Information
- Founded
- ACRS 2012
- GALT 2000
- Country
- ACRS United States
- GALT United States
- Employees
- ACRS N/A
- GALT N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- GALT Health Care
- Exchange
- ACRS Nasdaq
- GALT Nasdaq
- Market Cap
- ACRS 132.0M
- GALT 147.8M
- IPO Year
- ACRS 2015
- GALT N/A
- Fundamental
- Price
- ACRS $2.72
- GALT $1.04
- Analyst Decision
- ACRS Strong Buy
- GALT Strong Buy
- Analyst Count
- ACRS 5
- GALT 1
- Target Price
- ACRS $8.75
- GALT $11.00
- AVG Volume (30 Days)
- ACRS 1.1M
- GALT 1.1M
- Earning Date
- ACRS 11-06-2024
- GALT 11-13-2024
- Dividend Yield
- ACRS N/A
- GALT N/A
- EPS Growth
- ACRS N/A
- GALT N/A
- EPS
- ACRS N/A
- GALT N/A
- Revenue
- ACRS $27,079,000.00
- GALT N/A
- Revenue This Year
- ACRS N/A
- GALT N/A
- Revenue Next Year
- ACRS N/A
- GALT N/A
- P/E Ratio
- ACRS N/A
- GALT N/A
- Revenue Growth
- ACRS 26.35
- GALT N/A
- 52 Week Low
- ACRS $0.86
- GALT $0.73
- 52 Week High
- ACRS $5.17
- GALT $4.27
- Technical
- Relative Strength Index (RSI)
- ACRS 41.17
- GALT 20.80
- Support Level
- ACRS $2.91
- GALT $1.80
- Resistance Level
- ACRS $3.29
- GALT $2.36
- Average True Range (ATR)
- ACRS 0.29
- GALT 0.27
- MACD
- ACRS -0.18
- GALT -0.08
- Stochastic Oscillator
- ACRS 0.75
- GALT 15.07
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.